Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAung M. TunMHMehdi HamadaniTBTimothy Best

Discussion

Loading...

Member takes

Overview

Observational study found long-term responses and manageable safety for R/R follicular lymphoma, indicating a need to consider comorbidities and frailty.

Key Points

  • To investigate long-term effectiveness and safety outcomes of car T-cell therapy in relapsed or refractory follicular lymphoma patients.
  • Identified patients from CIBMTR registry receiving axi-cel between 03/2021–10/2023
  • Conducted descriptive analyses by age, comorbidities, and prior treatments
  • Used multivariable Cox and logistic regression to adjust for confounders.
  • Objective response rate was 96% with a complete response rate of 91%
  • At 2 years, disease-free survival was 64% and overall survival was 84%
  • Cytokine release syndrome occurred in 74%, with 4% being grade ≥3.

Cite This Study

Tun et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db4dhttps://doi.org/10.1182/blood-2025-5356
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term real-world outcomes of axicabtagene ciloleucel (axi-cel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL).2026
  2. 2Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study2025
  3. 3Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries2025
  4. 4Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE2025 · 2 citations
  5. 5Real-world outcomes of axicabtagene ciloleucel in older versus younger adults with diffuse large B-cell lymphoma.2026